A5083019296- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Angiogenesis and VEGF in Cancer
- Chronic Lymphocytic Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Cervical Cancer and HPV Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lipid metabolism and disorders
- Immunotherapy and Immune Responses
- CNS Lymphoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Endometrial and Cervical Cancer Treatments
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
- Thyroid Cancer Diagnosis and Treatment
- Syphilis Diagnosis and Treatment
- Ocular Oncology and Treatments
- Head and Neck Cancer Studies
- Acute Myocardial Infarction Research
Columbia University Irving Medical Center
2023-2025
Texas Health Dallas
2023
Columbia University
2023
State University of New York
2020-2021
SUNY Downstate Health Sciences University
2020-2021
Dana-Farber Brigham Cancer Center
2016
Brigham and Women's Hospital
2016
Dana-Farber Cancer Institute
2015-2016
Harvard University
2016
Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL, chromosome 9p24.1/PD-L1/PD-L2 alterations increase the abundance PD-1 ligands, PD-L1 and PD-L2, their further induction through Janus kinase 2-signal transducers activators transcription signaling. The unique composition cHL limits its analysis with high-throughput genomic assays. Therefore, precise incidence, nature,...
In classical Hodgkin lymphoma (cHL), malignant Reed-Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the ligands is attributable, in part, to copy number alterations 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) Amplification PD-L1/PD-L2 associated with advanced clinical stage inferior progression-free survival (PFS) following first-line (induction) therapy. The relationships between...
Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting clinical outcomes mechanisms to overcome resistance remain as critical needs. Angiogenesis is increasingly appreciated an immune modulator with potential combinatorial use blockade. Angiopoietin-2 (ANGPT2) target patients involved anti-VEGF treatment monoclonal antibody bevacizumab. We investigated predictive prognostic value circulating...
Patients with squamous cell carcinoma (SCC) of the cervix or vulva have limited therapeutic options, and potential for immunotherapy this population has not been evaluated. Recent trials suggest that tumors a genetic basis PD-1 (programmed death protein 1) ligand expression are highly sensitive to antibodies targeting PD-1.To determine status CD274 (encoding PD-L1 [programmed 1 1]) PDCD1LG2 PD-L2 2]) in SCCs correlate findings expression.We performed fluorescence situ hybridization (FISH)...
Abstract PD-L1 is the only approved biomarker for pembrolizumab in metastatic breast cancer response to combination chemo-immunotherapy. We searched tissue-based immune biomarkers of triple negative (mTNBC) patients prospectively treated with front-line chemoimmunotherapy on ENHANCE-1 study eribulin and pembrolizumab. used quantitative multiplexed immunofluorescence (qmIF) evaluate populations pre-treatment tissue characterize associations clinical outcomes. was a single arm phase Ib/II...
ABSTRACT Background Screening for cervical cancer may include cytology and/or high‐risk human papillomavirus testing (HPV). The FDA (Food and Drug Administration)‐approved CINtec PLUS dual stain (DS) p16 Ki‐67 can provide helpful information challenging follow‐up care. Methods We retrospectively analyzed 272 cases with negative intraepithelial malignancy (NILM) Papanicolaou (Pap) tests positive HPV test results. All women had colposcopy‐directed biopsies or endocervical curettage (ECC)...
Abstract We studied the incidence of HPV genotypes in mostly Black women with cervical carcinoma and correlated histopathologic tumor characteristics, immune markers clinical data survival. Disease-free survival (DFS) overall (OS) were recorded for 60 months post-diagnosis. Fifty four (90%) patients 36 (60%) < 55 years age. Of 40 typeable genotypes, 10 (25%) had 16/18 30 (75%) one non-16/18 20 (50%) 7 (35, 39, 51, 53, 56, 59 68) that are not included nonavalent vaccine. Mixed infections...
Approximately, 55% of breast carcinomas are reported to be HER-2 low carcinomas. Trastuzumab-Deruxtecan is a new FDA-approved targeted therapy for metastatic carcinomas, making it essential that all efforts made identify these tumors in specimens submitted pathologic examination. Cytology often the first and only modality this assessment due ease specimen procurement. This study aimed determine variability immunostaining interpretation among observers using cytologic from sites.
Ocular cytology is an effective method of diagnosing infective, benign, and malignant ocular disease processes due to easy accessibility rapid turnaround time. However, these specimens pose significant diagnostic challenges rarity the specimen type, sparse material available for ancillary workup, unfamiliarity entities by cytopathologist.
Among white rheumatoid arthritis (RA) cohorts, heart failure with preserved ejection fraction is the most prevalent type of (HF). We aimed to assess HF affecting Black RA patients. A total 64 patients RA-HF were compared age-, sex-, and race-matched without HF. Left ventricular fraction, wall motion abnormalities, left ventricle (LV) mass, thickness reviewed. About 87.3% 84.4% women, a mean age 69.6 ± 1.38 (± SEM) body mass index (kg/m 2 ) 29.6 1.07. had higher rates hypertension (HTN),...
Pancreaticobiliary carcinomas rarely harbor targetable genetic alterations, including microsatellite instability (MSI) or neurotrophic tyrosine receptor kinase (NTRK) gene fusions. As these malignancies are typically present at an advanced stage and have suboptimal response to chemotherapy, the discovery of actionable genomic alteration provides additional avenue treatment for chemotherapy-refractory cases.
Sarcoidosis is an idiopathic multisystem granulomatous disease that affects patients of all races and ethnic groups however predilection for women African Americans apparent. Extrapulmonary manifestations sarcoidosis occur in up to 50% cases. The most common sites extrapulmonary involvement are the skin, eyes, liver, reticuloendothelial system followed bt renal, cardiac, neurological involvement. We present case a middle age man with exclusive affecting hepatic, splenic central nervous...
Abstract Introduction/Objective Neisseria gonorrhoeae (NG) is the 2nd most common cause of sexually transmitted infection worldwide. WHO data from 2009-14 showed widespread resistance to ciprofloxacin (97%), azithromycin (81%), and oral cefixime injectable ceftriaxone (66%). We have investigated local epidemiology antimicrobial in PCR-confirmed NG by chromosomal multi-locus sequence typing analysis. Methods/Case Report Clinical specimens 85 patients who tested positive for using automated...
Abstract Background Treatment with combination chemo-immunotherapy has become the front-line standard for eligible patients PD-L1 positive mTNBC. is only approved biomarker pembrolizumab in metastatic breast cancer response to chemo-immunotherapy, however given that it not predictive of all cases additional biomarkers are needed. Tumor infiltrating lymphocytes (TILs) have been shown be both and prognostic operable TNBC, but there fewer data regarding role TILs In this study we report...
<p>Supplementary methods</p>
<div>Abstract<p>Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting clinical outcomes mechanisms to overcome resistance remain as critical needs. Angiogenesis is increasingly appreciated an immune modulator with potential combinatorial use blockade. Angiopoietin-2 (ANGPT2) target patients involved anti-VEGF treatment monoclonal antibody bevacizumab. We investigated predictive...
<div>Abstract<p>In classical Hodgkin lymphoma (cHL), malignant Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the ligands is attributable, in part, to copy number alterations 9p24.1/<i>CD274</i>(<i>PD-L1)/PDCD1LG2(PD-L2)</i>. Amplification <i>PD-L1/PD-L2</i> associated with advanced clinical stage inferior progression-free...
<p>Fig. S1. Kaplan-Meier survival curves of patients receiving ipilimumab or plus bevacizumab. Fig. S2. Clinical responses and PD-1 blockade-treated based on serum ANGPT2 fold changes. S3. Hypoxia upregulated expression in melanoma cells. S4. enhanced PD-L1 CSF1-activated MDM from healthy donors. S5. Antibody to clinical immune checkpoint therapy. S6. Enriched endogenous anti-ANGPT2 antibodies inhibited ANGPT2-mediated Erk1/2 phosphorylation.</p>
<p>Culture and treatment of endothelial cells melanoma cells. Generation polarization monocyte derived macrophages (MDM). Purification ANGPT2 antibodies from plasma. Immunoblot analyses.</p>